Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Genesis Biotechnology, Yale ink agreement
January 2019
SHARING OPTIONS:

HAMILTON, N.J.—The fourth quarter of 2018 saw Genesis Biotechnology Group—and Genesis Drug Discovery and Development (GD3), its contract research organization arm—share news of a partnership with Yale University. Under this collaboration, the organizations will offer a variety of drug discovery services to the awardees of the Blavatnik Fund for Innovation. The Fund, which supports faculty in commercializing research and technology, recently made a commitment of $25 million.
 
“We are delighted to partner with Yale University to accelerate the transition of fundamental biomedical discoveries into commercialization opportunities,” said Dr. Olesia Buiakova, chief scientific officer of GD3. “Our partnership with Yale is an important step forward for this program, and we look forward to developing a strong and mutually beneficial relationship with the Blavatnik Fund and Office of Cooperative Research at Yale.”

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2019 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.